Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
Clinical trial NCT04704219 · COMPLETED
Trial details
- NCT number
- NCT04704219
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-23
- Primary completion
- 2025-01-27
- Enrollment
- 160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.